Back to Search
Start Over
Updated analysis of phase 2 study of bendamustine and dexamethasone in patients with relapsed/refractory systemic light chain (AL) amyloidosis.
- Source :
- Amyloid; 2019 Supplement 1, Vol. 26, p113-114, 2p
- Publication Year :
- 2019
-
Abstract
- Highlights from the article: Patients with relapsed or refractory AL amyloidosis have limited treatment options. Out of 23 patients with evaluable organ response, 5 of 13 patients had a renal response and 1 of 14 patients had cardiac response. In patients with refractory and/or relapsed AL amyloidosis with limited therapeutic options Ben/Dex is a viable treatment option that produced a substantial hematologic response and increased survival.
Details
- Language :
- English
- ISSN :
- 13506129
- Volume :
- 26
- Database :
- Complementary Index
- Journal :
- Amyloid
- Publication Type :
- Academic Journal
- Accession number :
- 137680201
- Full Text :
- https://doi.org/10.1080/13506129.2019.1583200